JEOL (6951) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for Q3 of the fiscal year ending March 2026 reflected declines in both revenue and earnings, with deteriorating profitability in the core businesses being the primary cause of the decline in margins. Revenue was ¥1298.0B (down -4.8% YoY), Operating Income was ¥214.0B (down -18.6%), Ordinary Income was ¥236.6B (down -10.7%), and Net Income was ¥174.9B (down -12.3%). The Operating Margin was 16.5%, approximately 2.8pt lower than in the same period of the previous year, indicating that earnings contracted more than revenue. Foreign exchange gains in non-operating income and gains on sales of investment securities recorded in extraordinary income supported Ordinary Income and Net Income, while the decline in recurring earnings power was particularly evident in the fall in Operating Income.

Factors Affecting Performance

【Revenue】Revenue was ¥1298.0B, a decline of -4.8% YoY. By segment, the Scientific and Measuring Instruments Business was the largest downward factor, at ¥782.3B (60.3% of total, down -7.2%). The Industrial Equipment Business recorded a modest decline in revenue to ¥405.6B (31.3% of total, down -2.8%), while the Medical Equipment Business was the only segment to report revenue growth, at ¥110.2B (8.5% of total, up +6.9%). By region, Japan at ¥360.3B (up +9.9%) and North, Central and South America at ¥209.6B (up +6.3%) expanded, while China at ¥336.3B (down -6.3%) and Other regions at ¥391.8B (down -18.3%) declined, with slowing overseas demand weighing on overall performance.

【Profit and Loss】Operating Income was ¥214.0B (down -18.6%), and the Operating Margin declined to 16.5% from 19.3% in the same period of the previous year, a decrease of approximately 2.8pt. The profit margin of the Industrial Equipment Business declined from 48.8% to 44.0%, while that of the Scientific and Measuring Instruments Business declined to approximately 9.7%, indicating weaker fixed-cost absorption. Despite revenue growth, the Medical Equipment Business also saw its profit margin deteriorate from 7.6% to 6.4%. Ordinary Income was ¥236.6B (down -10.7%), boosted by foreign exchange gains of ¥9.6B included in non-operating income. Extraordinary income included ¥1.04B, of which ¥9.8B was gains on sales of investment securities, representing a temporary factor contributing to Pretax Income of ¥246.9B. Net Income was ¥174.9B (down -12.3%), resulting in declines in both revenue and earnings.

Segment Analysis

The Industrial Equipment Business remained the largest contributor to earnings, with revenue of ¥405.6B (31.3% of total) and segment profit of ¥178.4B (68.2% of total). However, compared with the same period of the previous year, revenue declined -2.8% and profit declined -12.4%, with the decline in profit being substantial. The Scientific and Measuring Instruments Business recorded revenue of ¥782.3B (60.3% of total) and segment profit of ¥76.0B (29.1% of total). Revenue declined -7.2% and profit declined -23.9% YoY, representing the largest decline in profit and the primary cause of the decrease in consolidated earnings. The Medical Equipment Business recorded revenue of ¥110.2B (8.5% of total) and segment profit of ¥7.1B (2.7% of total). Despite revenue growth (+6.9%), profit declined -8.9%, making the conversion of revenue growth into earnings a key challenge. Corporate expenses (adjustments) were ¥47.5B, slightly below ¥48.3B in the same period of the previous year.

Key Financial Indicators

【Profitability】The Operating Margin of 16.5% and Net Profit Margin of 13.5% both declined from the same period of the previous year (19.3% and 14.6%, respectively), but remained high in absolute terms. ROE was 11.7%, decomposed into Net Profit Margin of 13.5% × Total Asset Turnover of 0.554x × Financial Leverage of 1.57x, with low asset efficiency being the primary constraint on ROE. R&D expenses were ¥86.0B (6.6% of revenue), maintaining a level of continued technology investment. 【Cash Quality】Accounts receivable of ¥437.0B and work in process of ¥571.8B represent substantial portions of total assets of ¥2341.4B, creating a structure in which working-capital turnover efficiency determines the conversion of earnings into cash. Contract liabilities of ¥314.3B provide a degree of funding support as customer advances. 【Investment Efficiency】Property, plant and equipment of ¥341.1B, including construction in progress of ¥101.7B, has accumulated, and the progress of investment projects becoming operational will affect future asset efficiency. Goodwill of ¥8.4B and intangible assets of ¥46.6B are both small relative to total assets, limiting M&A-related risk. 【Financial Soundness】The Equity Ratio was 63.9% (up from 61.4% in the previous year). Interest-bearing debt (long-term borrowings of ¥82.9B plus the portion due within one year of ¥37.7B) is small relative to total assets and net assets, indicating a conservative financial structure. Cash and deposits were ¥380.5B, and current assets of ¥1688.2B substantially exceeded current liabilities of ¥652.6B.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is unavailable, financial trends can be inferred from changes in the balance sheet. Cash and deposits increased to ¥380.5B from ¥361.4B in the same period of the previous year, indicating that financial flexibility has been maintained. Meanwhile, accounts receivable of ¥437.0B and work in process of ¥571.8B each represent substantial proportions of total assets, creating a structure with significant funds tied up in working capital. Contract liabilities of ¥314.3B partially supplement funding as customer advances, but the period until cash conversion could lengthen if the completion and acceptance of work in process do not progress. Property, plant and equipment has expanded, including construction in progress, suggesting that capital investment is continuing. Interest-bearing debt is small, and investment and inventory accumulation are considered to have been financed primarily through growth in equity (net assets of ¥1495.1B versus ¥1366.5B in the previous year).

Earnings Quality

A meaningful portion of current-period earnings includes contributions from non-recurring items, which must be distinguished when assessing earnings quality. Of non-operating income of ¥24.3B, foreign exchange gains accounted for ¥9.6B and contributed to the increase in Ordinary Income of ¥236.6B. Most of extraordinary income of ¥10.4B consisted of ¥9.8B in gains on sales of investment securities, a temporary factor equivalent to approximately 4.0% of Pretax Income of ¥246.9B. Extraordinary losses were negligible at ¥0.1B, and extraordinary gains and losses had a net positive impact on earnings. Comprehensive Income was ¥195.7B, and the difference from Net Income of ¥174.9B was primarily attributable to foreign currency translation adjustments of ¥17.9B and valuation differences on securities of ¥10.0B, representing changes in unrealized gains and losses separate from the earning power of the underlying businesses. Looking at the flow from Operating Income to Net Income, recurring business earnings (Operating Income) fell significantly by -18.6% YoY, while temporary boosts from non-operating and extraordinary gains and losses relatively moderated the declines in Ordinary Income and Net Income (-10.7% and -12.3%, respectively). This point should be noted when evaluating earnings quality.

Earnings Forecast and Guidance

The full-year company plan calls for Revenue of ¥1810.0B (down -8.0% YoY), Operating Income of ¥240.0B (down -32.4%), and Ordinary Income of ¥245.0B (down -28.8%), with no revisions to the earnings forecast or dividend forecast. The cumulative Q3 progress rates were 71.7% for Revenue, 89.2% for Operating Income, and 96.6% for Ordinary Income, with progress below Operating Income substantially exceeding revenue progress. This means that while Q4 Revenue of ¥511.96B (the difference from the full-year plan) is expected, the required Operating Income is only ¥26.02B, implying that the plan incorporates a margin below the cumulative Operating Margin of 16.5%. The high progress rates for Ordinary Income and Net Income also include contributions from temporary factors such as foreign exchange gains and gains on sales of investment securities. The trend in the Q4 Operating Margin will be key to achieving the plan.

Shareholder Returns

The Q2 dividend was ¥53.00 per share, equivalent to 50% of the full-year forecast dividend of ¥106.00. There has been no revision to the dividend forecast. Based on the full-year Net Income plan of ¥180.0B and the average number of shares outstanding during the period of 51.15 million shares, the Payout Ratio is calculated at approximately 30.1%, below the level generally regarded as an indicator of sustainability. In addition to retained earnings of ¥977.4B and cash and deposits of ¥380.5B, the company has limited interest-bearing debt and a minimal interest burden, so financial constraints on dividend payments are limited.

Risk Factors

1. Deterioration in profitability of core businesses: The Scientific and Measuring Instruments Business saw segment profit decline -23.9% against a revenue decline of -7.2%, while the profit margin of the Industrial Equipment Business declined from 48.8% to 44.0%. As these two businesses account for more than 97% of consolidated segment profit, continued deterioration in profitability would directly affect consolidated earnings.

2. Regional concentration of overseas demand: While revenue in China declined -6.3% and revenue in Other regions declined -18.3%, Japan and North, Central and South America recorded revenue growth. The company therefore remains highly sensitive to overseas capital investment demand, foreign exchange rates, and geopolitical factors.

3. Funds tied up in working capital: Work in process of ¥571.8B accounts for approximately 34% of current assets and is thought to reflect the manufacturing characteristics of large-scale, long-lead-time projects. Together with accounts receivable of ¥437.0B, this creates a risk that the period during which funds are tied up from order receipt to cash collection may lengthen. Although contract liabilities of ¥314.3B provide a degree of mitigation, progress management for acceptance and delivery will be important.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

The company's profitability substantially exceeds the industry median and ranks at a high level within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate is below the industry median and relatively underperforms the industry average, which is on a revenue-growth trajectory.

※Source: Company compilation

Key Points from the Earnings Results

1. Although the Operating Margin of 16.5% and Net Profit Margin of 13.5% exceed industry levels, margin declines from the same period of the previous year have continued. In particular, future trends in the profit margins of the core Scientific and Measuring Instruments Business and Industrial Equipment Business will be a key focus.

2. Under the full-year plan, there is a gap between the Revenue progress rate of 71.7% and the Operating Income progress rate of 89.2%, creating a structure in which Q4 revenue mix and margin changes will determine the full-year outcome.

3. Financial soundness is favorable, as indicated by an Equity Ratio of 63.9% and the low level of interest-bearing debt. However, the efficiency of working capital, as reflected in the levels of work in process and accounts receivable, requires monitoring to determine whether earnings power can be converted into cash generation.

Theoretical Share Price (Reference Value)

Sensitivity: 3,181円〜3,370円 at Cost of Equity ±1%, and 3,265円〜3,286円 at ω±0.1.

Notes:

• Because Net Income progress against the full-year forecast (97%) exceeds the standard level (75%), Forecast EPS has been adjusted upward within a maximum of +10% (because companies with progress ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was resilient relative to the full-year plan but weaker year on year, with lower sales and a pronounced operating-margin decline. Nine-month revenue declined 4.8% year on year to ¥129.8bn. Operating income fell 18.6% to ¥21.4bn, materially underperforming the sales trend. Net income attributable to owners declined 12.3% to ¥17.5bn. The gross margin contracted 126bp year on year to 48.0%. The operating margin contracted 280bp to 16.5%, although it remains above the 15% benchmark generally considered excellent. The larger operating-profit decline reflects gross profit falling ¥4.9bn while SG&A was essentially flat, rising only ¥0.03bn. The net margin declined 115bp to 13.5% but remained strong in absolute terms. Ordinary income declined less sharply than operating income, by 10.7%, supported by ¥0.96bn of foreign-exchange gains and a low interest burden. Profit before tax also benefited from ¥1.04bn of extraordinary income, including a ¥0.98bn gain on sales of investment securities. This securities gain represented 5.6% of nine-month net income, meaning headline net income contains a meaningful non-recurring contribution. The Industrial Equipment business remained the core earnings contributor, generating ¥17.8bn of segment profit, or 68.2% of aggregate segment profit before corporate-cost allocation. China and other overseas markets were the main regional sources of revenue weakness, while Japan and the Americas expanded. The company has already achieved 89.2% of full-year operating-income guidance and 97.2% of net-income guidance after nine months, versus a standard 75% Q3 progress rate. The full-year guidance consequently embeds a much weaker fourth quarter, particularly for profit, and execution against that implied seasonality is the central near-term earnings issue. The balance sheet remains highly liquid and conservatively financed despite increased borrowing and a substantial construction-in-progress balance. Working-capital intensity, especially work in process, is the principal operational risk that could pressure cash conversion.

Profitability Analysis

Annualized DuPont ROE is 15.6%, decomposed into a 13.5% net profit margin, 0.739x asset turnover, and 1.57x financial leverage. This places ROE just above the 15% excellence threshold, with profitability rather than leverage providing the main support. Financial leverage is modest, so the return profile is not dependent on aggressive debt financing. The principal deterioration is in margins: gross margin declined from 49.3% to 48.0%, while operating margin fell from 19.3% to 16.5%. The 280bp operating-margin compression exceeded the 126bp gross-margin decline because SG&A remained flat at ¥40.9bn despite a ¥6.5bn revenue reduction. This is adverse operating leverage, with the ¥4.9bn gross-profit decline almost fully translating into the ¥4.9bn operating-income reduction. R&D expense was ¥8.6bn, equivalent to 6.6% of revenue and within the typical 5-15% range for technology and electronics-oriented manufacturers; it was down only 0.9% year on year, indicating that development investment was broadly protected through the downturn. The Industrial Equipment segment is the core business by operating-income contribution, reporting revenue of ¥40.6bn, down 2.8% year on year, and segment profit of ¥17.8bn, down 12.4%; its segment margin nonetheless remained very high at 44.0%, versus 48.8% a year earlier. Scientific and Measuring Instruments reported revenue of ¥78.2bn, down 7.2%, and segment profit of ¥7.6bn, down 23.9%, with margin falling to 9.7% from 11.8%. Medical Equipment was the only segment to grow revenue, up 6.9% to ¥11.0bn, but segment profit declined 8.9% to ¥0.7bn and margin fell to 6.4% from 7.6%. Corporate costs were ¥4.8bn, broadly stable year on year, limiting flexibility to offset weaker segment profitability. The extended DuPont tax burden was normal at 0.708 and the interest burden was favorable at 1.154, reflecting net non-operating gains rather than debt-related pressure. Interest coverage was exceptionally strong at 301.4x.

Growth Assessment

Revenue momentum was uneven across products and regions. Japan revenue increased 9.9% year on year to ¥36.0bn and North, Central and South America increased 6.3% to ¥21.0bn. In contrast, China revenue declined 6.3% to ¥33.6bn and other overseas markets declined 18.3% to ¥39.2bn. The Scientific and Measuring Instruments business accounted for the largest absolute revenue decline, falling ¥6.1bn year on year, and its lower segment margin made it the main segment-level source of earnings pressure. Industrial Equipment sales were comparatively resilient, but the segment's ¥2.5bn profit decline demonstrates that pricing, mix, utilization or input-cost absorption weakened even in the highest-margin business. Medical Equipment growth is constructive, but its small profit contribution means it did not offset weakness in the other two businesses. R&D spending of ¥8.6bn supports the technology pipeline and reduces the risk that short-term margin protection comes at the expense of future competitiveness. Full-year sales guidance is ¥181.0bn, implying fourth-quarter revenue of ¥51.2bn and a 71.7% progress rate at Q3, modestly below the standard 75% pace. Full-year operating-income guidance of ¥24.0bn implies only ¥2.6bn of fourth-quarter operating income, while ordinary-income guidance of ¥24.5bn implies ¥0.85bn and net-income guidance of ¥18.0bn implies ¥0.51bn. The 89.2% operating-profit, 96.6% ordinary-income and 97.2% net-income progress rates are more than 10 percentage points above normal Q3 seasonality. This guidance profile indicates management expects a sharp fourth-quarter earnings slowdown, potentially reflecting shipment timing, product mix, costs, or conservative assumptions. No forecast revision has been announced, so the gap between accumulated earnings and the implied fourth-quarter outcome should be monitored alongside order execution and regional demand trends.

Financial Health

Liquidity is strong, with a current ratio of 258.7%, a quick ratio of 230.4%, and working capital of ¥103.6bn. Current assets of ¥168.8bn substantially exceed current liabilities of ¥65.3bn, limiting maturity-mismatch risk. Cash and deposits were ¥38.0bn, while receivables were ¥43.7bn and contract liabilities were ¥31.4bn. The reported debt-to-equity ratio of 0.57x is conservative and remains well below the 2.0x warning threshold; this reported measure broadly reflects total liabilities relative to equity. Interest-bearing debt was ¥8.3bn in long-term loans, with ¥3.8bn of current portions of long-term loans, and is small relative to ¥149.5bn of equity and ¥38.0bn of cash. Debt/capital was only 5.3%, while interest coverage of 301.4x confirms minimal financing stress. Total equity increased ¥12.9bn year on year to ¥149.5bn, supported by retained earnings rising ¥11.6bn to ¥97.7bn and positive comprehensive income. Long-term loans increased ¥5.1bn, or 161.5%, to ¥8.3bn; while still manageable, the increase should be assessed against the company's expanded investment program. PPE increased ¥10.0bn, or 41.5%, to ¥34.1bn, led by construction in progress of ¥10.2bn. Construction in progress represented 29.8% of PPE, above the 20% quality-alert threshold, indicating a sizable project pipeline and heightening the importance of project completion, budget discipline, and returns on invested capital. Net defined-benefit liability was ¥8.0bn and asset-retirement obligations were ¥0.4bn, both manageable relative to the capital base. Goodwill was only ¥0.8bn, equal to 0.6% of equity and 0.4% of assets, so balance-sheet exposure to JGAAP goodwill amortization or impairment is immaterial. Intangible assets were 2.0% of total assets, also indicating limited acquisition-accounting risk.

Notable B/S Changes

Long-term loans: +¥5.1bn (+161.5%) to ¥8.3bn - borrowing increased sharply from a low base, likely alongside the investment build-out; leverage remains conservative but capital deployment and project returns should be monitored. PPE: +¥10.0bn (+41.5%) to ¥34.1bn - substantial fixed-asset expansion, led by ¥10.2bn of construction in progress; the 29.8% CIP/PPE ratio creates completion, cost-control, and utilization risk. Construction in progress: +¥9.0bn to ¥10.2bn - the investment pipeline expanded sharply and now represents 29.8% of PPE, above the 20% quality-alert threshold. Treasury stock: -¥0.8bn (-116.0%) to -¥1.5bn - larger treasury-share holdings reduced reported equity modestly and should be considered separately from dividend distributions when assessing total shareholder returns. Retained earnings: +¥11.6bn (+13.4%) to ¥97.7bn - accumulated profitability continues to strengthen internal funding capacity and supports financial flexibility. Receivables: -¥8.0bn (-15.5%) to ¥43.7bn - the balance declined, but the annualized DSO alert remains elevated at 92 days because revenue also weakened. Finished goods: +¥2.6bn (+16.0%) to ¥18.5bn and work in process: +¥1.6bn (+2.1%) to ¥57.2bn - the already WIP-heavy inventory structure remains capital intensive, with WIP representing 70.3% of inventory.

Cash Flow Quality

The operating cycle warrants close attention because receivables, work in process, and capital projects absorb substantial balance-sheet resources. The quality alert for receivable days identifies DSO of 92 days, above the 60-day warning threshold. This indicates relatively slow conversion of recognized sales into cash, elevating collection and customer-credit exposure. The inventory-days alert reports DIO of 330 days, substantially above the 90-day warning level. A separate inventory-days alert of 75 days also exceeds the 60-day manufacturing benchmark; both indicators point to an inventory-intensive operating model. The cash conversion cycle is flagged at 380 days, far above the 120-day warning threshold, so modest shifts in production or customer collections can have a material effect on liquidity. Work in process was ¥57.2bn and represented 70.3% of total inventory, well above the 40% alert threshold. This concentration is a concern because WIP is less readily monetized than finished goods and can indicate long production lead times, production bottlenecks, delayed acceptance, or heightened risk of cost overruns and obsolescence if demand changes. Finished goods were ¥18.5bn and raw materials were ¥5.7bn, reinforcing that the working-capital issue is predominantly in-process production rather than raw-material stocking. Accounts payable were ¥10.3bn and electronically recorded obligations were ¥3.9bn, providing some supplier financing but not enough to neutralize the long cash-conversion cycle. The elevated construction-in-progress balance compounds the cash-demand profile because capital projects and WIP are both consuming capital concurrently. The company’s strong cash balance and liquidity ratios provide a meaningful buffer, but improvement in receivable collection, production throughput, inventory completion, and project commissioning is important for cash conversion.

Dividend Sustainability

The interim dividend was ¥53 per share, and the indicated full-year dividend is ¥106 per share. Based on full-year EPS guidance of ¥352.09, the implied dividend payout ratio is approximately 30.1%, which is well below the 60% sustainability benchmark. The interim dividend alone represented a 15.6% payout ratio against nine-month net income. The planned full-year dividend is double the ¥53 interim payment and is consistent with a stable year-end payment assuming the full-year forecast is delivered. Retained earnings of ¥97.7bn, strong liquidity, low interest-bearing debt, and low debt/capital provide substantial balance-sheet capacity to support the dividend. The key determinant of dividend resilience is therefore operational cash conversion rather than accounting profitability, given the elevated receivable days, inventory days, WIP concentration, and construction-in-progress balance. Treasury stock increased by ¥0.8bn year on year to a negative ¥1.5bn balance; this indicates greater treasury-share holdings, but the disclosed data do not quantify repurchase cash outlays, so dividend payout is assessed separately from total shareholder returns. The current dividend policy appears financially supportable on earnings and capital-structure metrics, subject to discipline in working-capital and capital-project execution.

Risk Assessment

Business risks include Demand and mix risk: China revenue fell 6.3% year on year and other overseas revenue fell 18.3%, exposing the group to weaker capital-expenditure conditions in major international markets., Scientific and Measuring Instruments risk: segment revenue declined 7.2% and segment profit declined 23.9%, with margin falling 210bp to 9.7%; a prolonged recovery in this business would constrain consolidated profit growth., Industrial Equipment margin risk: the core earnings segment retained a 44.0% margin, but that margin fell 480bp year on year, indicating significant sensitivity to volume, product mix, price, and manufacturing-cost absorption., Manufacturing execution risk: WIP of ¥57.2bn, equal to 70.3% of inventory, is above the 40% warning threshold and may reflect long production cycles, bottlenecks, delayed delivery, or inventory obsolescence risk., Industry-specific technology and equipment-cycle risk: demand for scientific instruments, industrial equipment, and medical equipment is sensitive to customers' research budgets, semiconductor and industrial investment cycles, export conditions, and procurement lead times., Foreign-exchange risk: nine-month foreign-exchange gains were ¥0.96bn, supporting ordinary income; future currency moves could reverse this benefit and add volatility to earnings..

Financial risks include Working-capital risk: DSO of 92 days, DIO alerts of 330 days and 75 days, and a 380-day cash conversion cycle are all above warning thresholds, increasing the risk of cash being tied up in operations., Capital-project risk: construction in progress of ¥10.2bn is 29.8% of PPE, above the 20% alert threshold; delayed completion, cost escalation, or inadequate utilization could reduce future returns., Borrowing trend risk: long-term loans rose 161.5% year on year to ¥8.3bn. Leverage remains low, but incremental debt should be matched by timely benefits from the expanded PPE base., Non-recurring profit risk: the ¥0.98bn gain on sale of investment securities was 5.6% of net income, supporting reported earnings but not recurring operating cash generation..

Key concerns include Highest priority: normalize the cash conversion cycle through faster receivable collection and conversion of WIP into completed, accepted, and paid-for products., High priority: determine whether the core Industrial Equipment segment’s 480bp margin compression is cyclical or evidence of more persistent price or cost pressure., High priority: monitor fourth-quarter delivery and profitability because full-year guidance implies operating profit of only ¥2.6bn after ¥21.4bn was earned in the first nine months., Medium priority: assess the return profile and completion schedule of the large construction-in-progress balance., Medium priority: distinguish recurring earnings from FX gains and gains on sales of investment securities when evaluating profit momentum..

Investment Implications

Key takeaways include Profitability remains strong, with a 16.5% operating margin, 13.5% net margin, and annualized ROE of 15.6%, but each key earnings measure declined year on year., The Industrial Equipment segment is the core profit engine, contributing 68.2% of aggregate segment profit before corporate costs, yet its margin contraction is the most important earnings sensitivity., Japan and the Americas grew, whereas China and other overseas markets weakened, creating a mixed geographic demand backdrop., The balance sheet is robust, with a 258.7% current ratio, 5.3% debt/capital, and 301.4x interest coverage., Operational capital intensity is elevated: high WIP, long receivable and inventory days, a 380-day cash conversion cycle, and high construction in progress require close monitoring., Nine-month earnings are substantially ahead of the full-year plan, but the implied fourth-quarter profit slowdown makes timing of shipments, costs, and guidance assumptions highly relevant..

Metrics to watch include Industrial Equipment segment margin and order conversion, Scientific and Measuring Instruments revenue recovery and segment margin, China and other overseas regional revenue trends, DSO of 92 days, DIO alerts of 330 days and 75 days, and the 380-day cash conversion cycle, WIP balance and WIP share of inventory, Construction-in-progress completion, PPE utilization, and incremental borrowing, Fourth-quarter revenue and operating income versus the implied ¥51.2bn and ¥2.6bn, respectively, Recurring earnings excluding foreign-exchange gains and securities-sale gains.

Regarding relative positioning, Japan Electron combines above-benchmark profitability and a very strong liquidity/solvency profile with a materially more demanding working-capital profile than efficient manufacturing benchmarks. Its low goodwill exposure and low financial leverage are relative strengths, while margin compression in the core Industrial Equipment business, overseas demand softness, and unusually long production-to-cash conversion are the principal factors shaping relative earnings quality.